Patents Assigned to Biogen Idec
  • Patent number: 8551476
    Abstract: Endogenous Sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination (Negative Regulator). Molecules that block endogenous Sp35 function, such anti-Sp35 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for Sp35, and methods of using such antibodies as antagonists of endogenous Sp35 function. The invention further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies. The invention further provides methods of promoting oligodendrocyte survival and myelination in a vertebrate, comprising administering to a vertebrate in need of such treatment an effective amount of an anti-Sp35 antibody.
    Type: Grant
    Filed: August 17, 2007
    Date of Patent: October 8, 2013
    Assignee: Biogen Idec MA Inc.
    Inventors: Sha Mi, R. Blake Pepinsky, Zhaohui Shao, Christilyn Graff
  • Publication number: 20130259861
    Abstract: This invention relates to methods of treating disease with soluble inhibitors of the lymphotoxin pathway having improved properties. This invention also relates to improved LTBR-Ig fusion proteins, and pharmaceutical compositions thereof.
    Type: Application
    Filed: November 20, 2012
    Publication date: October 3, 2013
    Applicant: BIOGEN IDEC MA INC.
    Inventors: Evan BECKMAN, Graham K. FARRINGTON, Werner MEIER, Jeffrey L. BROWNING
  • Patent number: 8545843
    Abstract: The present invention concerns treatment of autoimmune diseases with antagonists which bind to B cell surface markers, such as CD19 or CD20.
    Type: Grant
    Filed: September 20, 2010
    Date of Patent: October 1, 2013
    Assignees: Genentech, Inc., Biogen Idec Inc.
    Inventors: John G. Curd, Antonio J. Grillo-Lopez
  • Patent number: 8546359
    Abstract: Compounds that have agonist activity at one or more of the SIP receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at SIP receptors.
    Type: Grant
    Filed: September 10, 2012
    Date of Patent: October 1, 2013
    Assignee: Biogen Idec MA Inc.
    Inventors: Richard D. Caldwell, Kevin M. Guckian, Gnanasambandam Kumaravel, Wen-Cherng Lee, Edward Yin-Shiang Lin, Xiaogao Liu, Bin Ma, Daniel M. Scott, Zhan Shi, Jermaine Thomas, Arthur G. Taveras, Guo Zhu Zheng
  • Publication number: 20130237477
    Abstract: Disclosed are methods of increasing vascularization in a tissue by administering a neublastin polypeptide to a mammal exhibiting impaired or inadequate blood flow in the tissue. The methods can be used to in the treatment or prevention of a disorder characterized by impaired or inadequate blood flow or to increase vascularization in an organ that has been transplanted into a subject.
    Type: Application
    Filed: November 16, 2012
    Publication date: September 12, 2013
    Applicants: INSERM (Institut de la Sante et de la Recherche Medicale), BIOGEN IDEC MA INC.
    Inventors: Anthony Rossomando, Jean-Sebastien Silvestre, Radia Tamarat
  • Patent number: 8524773
    Abstract: The present invention relates to the use of certain dialkyl fumarates for the preparation of pharmaceutical preparations for use in transplantation medicine or for the therapy of autoimmune diseases and said compositions in the form of micro-tablets or pellets. For this purpose, the dialkyl fumarates may also be used in combination with conventional preparations used in transplantation medicine and immunosuppressive agents, especially cyclosporines.
    Type: Grant
    Filed: September 12, 2012
    Date of Patent: September 3, 2013
    Assignee: Biogen Idec International GmbH
    Inventors: Rajendra Kumar Joshi, Hans-Peter Strebel
  • Patent number: 8524660
    Abstract: The invention relates to novel polyalkylene glycol compounds and methods of using them. In particular, compounds comprising a novel polyethylene glycol conjugate are used alone, or in combination with antiviral agents to treat a viral infection, such as chronic hepatitis C.
    Type: Grant
    Filed: September 12, 2011
    Date of Patent: September 3, 2013
    Assignee: Biogen Idec MA Inc.
    Inventors: KoChung Lin, R. Blake Pepinsky, Ling Ling Chen, Donna M. Hess, Edward Y. Lin, Russell C. Petter, Darren P. Baker
  • Patent number: 8524672
    Abstract: Disclosed are nucleic acids encoding BAFF-R polypeptides, as well as antibodies to BAFF-R polypeptides and pharmaceutical compositions including the same. Methods of treating tumorigenic and autoimmune conditions using the nucleic acids, polypeptides, antibodies and pharmaceutical compositions of this invention are also provided.
    Type: Grant
    Filed: August 19, 2011
    Date of Patent: September 3, 2013
    Assignee: Biogen Idec MA Inc.
    Inventors: Christine M. Ambrose, Jeffrey S. Thompson
  • Patent number: 8519112
    Abstract: The invention provides humanized antibodies that bind to a plurality of ?-chemokines, particularly monocyte chemotactic proteins MCP-1, MCP-2 and MCP-3. The invention also provides therapeutic reagents and methods of treating disorders associated with detrimental MCP activity.
    Type: Grant
    Filed: February 14, 2011
    Date of Patent: August 27, 2013
    Assignee: Biogen Idec MA Inc.
    Inventors: Antonin R. De Fougerolles, Victor E. Kotelianski, Ellen Garber, Carl Reid, Jose W. Saldanha, Herman Van Vlijmen
  • Publication number: 20130216496
    Abstract: The present invention provides methods and agents for the treatment of TWEAK-related conditions, including cardiac, liver, kidney, lung, adipose, skeletal, muscle, neuronal, bone and cartilage conditions. The invention also provides methods for identifying TWEAK agonists or antagonists for the treatment of TWEAK-related conditions. Additionally, the invention provides transgenic animals that express an exogenous DNA encoding a TWEAK polypeptide, or fragments, analogs, or muteins thereof, and methods for using such animals to identify TWEAK agonists or antagonists. The invention further provides methods for diagnosing a disease based on TWEAK expression. The invention also provides methods for affecting cellular differentiation of progenitor cells using TWEAK polypeptides, agonists, or antagonists.
    Type: Application
    Filed: April 11, 2013
    Publication date: August 22, 2013
    Applicant: BIOGEN IDEC MA INC.
    Inventors: Linda C. Burkly, Aniela Jakubowski, Timothy Zheng, Kyungmin Hahm
  • Publication number: 20130216557
    Abstract: The invention provides compositions and methods for predicting therapeutic responsiveness of a subject having an autoimmune disorder to an agent that inhibits signaling via LT?R based on the level of expression of IFN or a marker thereof in the subject. The invention also provides methods of treating selected subjects with agents that inhibit or reduce signaling vial LT?R.
    Type: Application
    Filed: August 15, 2011
    Publication date: August 22, 2013
    Applicant: Biogen Idec MA Inc.
    Inventors: Jadwiga Bienkowska, Jeffrey L. Browning
  • Publication number: 20130216513
    Abstract: Chimeric clotting factors which localize the therapeutic to sites of coagulation (e.g., by being targeted to platelets or being activatable at sites of coagulation), have reduced clearance rates, have improved manufacturability, have reduced thrombogenicity, have enhanced activity, or have more than one of these characteristics are described as are methods for making chimeric clotting factors and methods for improving hemostasia using these clotting factors.
    Type: Application
    Filed: July 11, 2011
    Publication date: August 22, 2013
    Applicant: Biogen Idec Hemophilia Inc.
    Inventors: Joe Salas, Robert Peters, Alan Bitonti
  • Patent number: 8512692
    Abstract: Liquid interferon compositions having a pH between 4.0 and 7.2 are described. The compositions comprise interferon-beta and a stabilizing agent at between about 0.3% and 5% by weight which is an amino acid selected from the group consisting of acidic amino acids, arginine and glycine. If needed, salt is added to provide sufficient ionic strength. The liquid composition has not been previously lyophilized or previously cavitated. The liquid is preferably contained within a vessel having at least one surface in contract with the liquid that is coated with a material inert to adsorption of interferon-beta. A kit for parenteral administration of a liquid interferon formulation and a method for stabilizing liquid interferon compositions are also described.
    Type: Grant
    Filed: June 4, 2010
    Date of Patent: August 20, 2013
    Assignee: Biogen Idec Ma Inc.
    Inventors: Mary D. DiBiase, Wen-Li Chung, Mark Staples, Eric Scharin
  • Patent number: 8512691
    Abstract: Liquid interferon compositions having a pH between 4.0 and 7.2 are described. The compositions comprise interferon-beta and a stabilizing agent at between about 0.3% and 5% by weight which is an amino acid selected from the group consisting of acidic amino acids, arginine and glycine. If needed, salt is added to provide sufficient ionic strength. The liquid composition has not been previously lyophilized or previously cavitated. The liquid is preferably contained within a vessel having at least one surface in contact with the liquid that is coated with a material inert to adsorption of interferon-beta. A kit for parenteral administration of a liquid interferon formulation and a method for stabilizing liquid interferon compositions are also described.
    Type: Grant
    Filed: October 18, 2007
    Date of Patent: August 20, 2013
    Assignee: Biogen Idec Ma Inc.
    Inventors: Mary D. DiBiase, Wen-Li Chung, Mark Staples, Eric Scharin
  • Patent number: 8506958
    Abstract: The present invention provides methods and agents for the treatment of TWEAK-related conditions, including cardiac, liver, kidney, lung, adipose, skeletal, muscle, neuronal, bone and cartilage conditions. The invention also provides methods for identifying TWEAK agonists or antagonists for the treatment of TWEAK-related conditions. Additionally, the invention provides transgenic animals that express an exogenous DNA encoding a TWEAK polypeptide, or fragments, analogs, or muteins thereof, and methods for using such animals to identify TWEAK agonists or antagonists. The invention further provides methods for diagnosing a disease based on TWEAK expression. The invention also provides methods for affecting cellular differentiation of progenitor cells using TWEAK polypeptides, agonists, or antagonists.
    Type: Grant
    Filed: April 3, 2009
    Date of Patent: August 13, 2013
    Assignee: Biogen IDEC MA Inc.
    Inventors: Linda C. Burkly, Aniela Jakubowski, Timothy Zheng, Kyungmin Hahm
  • Publication number: 20130202595
    Abstract: The present invention provides methods of administering Factor IX; methods of administering chimeric and hybrid polypeptides comprising Factor IX; chimeric and hybrid polypeptides comprising Factor IX; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
    Type: Application
    Filed: July 11, 2011
    Publication date: August 8, 2013
    Applicant: Biogen Idec Hemophilia Inc.
    Inventors: Glenn Pierce, Samantha Truex, Robert T. Peters, Haiyan Jiang
  • Publication number: 20130202596
    Abstract: The present invention features inter alia nucleic acid molecules which encode polypeptides comprising a single chain Fc region and the polypeptides they encode. The Fc moieties of these constructs are linked by a cleavable scFc linker which is adjacent to at least one enzymatic cleavage site, e.g., an intracellular processing site. The resulting processed molecules comprise two polypeptide chains and substantially lack the extraneous amino acid sequence found in single chain Fc linker molecule. Methods of making and using these dimeric molecules are also described.
    Type: Application
    Filed: July 11, 2011
    Publication date: August 8, 2013
    Applicant: BIOGEN IDEC HEMOPHILIA INC.
    Inventors: Joe Salas, Robert Peters
  • Patent number: 8501178
    Abstract: The present invention relates to Death Receptor-6 (DR6) proteins which are members of the tumor necrosis factor (TNF) receptor family, and have now been shown to be important for regulating apoptosis in cells of the nervous system. In addition, it has been discovered that p75 is a ligand for DR6. As a result, this invention relates to methods for inhibiting the interaction of DR6 and p75 using DR6 and/or p75 antagonists. In addition, the methods described herein include methods of promoting survival of cells of the nervous system using DR6 antagonists, optionally in combination with p75 antagonists, and methods of treating neurodegenerative conditions by the administration of a DR6 antagonists, optionally in combination with a p75 antagonist.
    Type: Grant
    Filed: November 24, 2009
    Date of Patent: August 6, 2013
    Assignee: Biogen Idec MA Inc.
    Inventors: Sha Mi, Kenneth J. Rhodes, R. Blake Pepinsky
  • Publication number: 20130196351
    Abstract: The present disclosure provides compositions and methods relating to the evaluation of BAFF in a biological sample from a subject.
    Type: Application
    Filed: March 8, 2013
    Publication date: August 1, 2013
    Applicant: BIOGEN IDEC MA INC.
    Inventor: BIOGEN IDEC MA INC.
  • Publication number: 20130196376
    Abstract: Methods for high level expression of active lymphotoxin-? receptor immunoglobulin chimeric proteins and their purification.
    Type: Application
    Filed: July 19, 2012
    Publication date: August 1, 2013
    Applicant: Biogen Idec MA Inc.
    Inventors: Jeffrey L. Browning, Konard Miatkowski, Werner Meier